Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- 22 Jul 2014
- Blog Post
From FIELD to Field, Putting What I’ve Learned at HBS into Practice
simple and clear as they appeared at first glance. The many times I was pushed to justify my stance – from the morality and ethicality of pharmaceutical patents in the developing world to the negotiation tactics I would use with Steve... View Details
- 01 Sep 2012
- News
A Silent Workplace Crisis
pharmaceuticals, the gap between the medical and the mental health systems, and the time required to find community resources and quality home care. My previous experience as a pharmaceutical executive and management consultant seemed... View Details
- 01 Jun 2000
- News
The Right Connections
prospectuses of all public biotech firms going back twenty years. Information from 295 companies and more than 3,000 executives formed the core of their study. The results showed that top managers' ties to notable pharmaceutical companies... View Details
Keywords: Judith A. Ross
- 01 Mar 2005
- News
Facing Ambiguity
successfully executed in a paper case.” The case, which will be taught this spring in the MBA second-year course General Management: Processes and Action, debuted last fall in a customized Executive Education program for a group of View Details
- Profile
Thomas Grenier
passion and by the many opportunities to indulge my own passions and interests, such as exploring the pharmaceuticals and healthcare fields through specialized coursework and a field study with a very promising medical imaging start-up.... View Details
- 24 Aug 2020
- Blog Post
My Journey to Joining the first MS/MBA Biotechnology: Life Sciences Cohort
forecasting expected revenues, to developing an equity investing plan for a major pharmaceutical company and performing due diligence on M&A targets. I also spent four months on secondment within a pharma company's Commercial Oncology... View Details
- 01 Sep 2010
- News
Reinventing the Annual Report
in this effort, including Southwest Airlines (with its Southwest Airlines One Report), United Technologies Corporation (UTC), the Dutch electronics and health-care giant Philips, the German chemical company BASF, and Danish pharmaceutical... View Details
Keywords: Robert G. Eccles
- 24 Sep 2020
- News
The Race for a Vaccine
headlines, the vaccine sector was a pretty sleepy space. Interest in vaccine development and production had been on the decline for decades. In the 1960s—the triumphant years after Jonas Salk discovered the first polio vaccine—there were 26 View Details
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side... View Details
Keywords: Sean Silverthorne
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term... View Details
- 04 Feb 2019
- Blog Post
Presenting…an Alternative to Company Presentations: Evercore Grabs Attention with Interactive Events
case study. When they added two more ingredients to the recipe – a focus on a familiar industry, amplified by media exposure the audience would recognize – they arrived at the heart of their presentation; a “live” case study about Evercore’s role in a recent M&A:... View Details
- 01 Oct 1998
- News
Going Against the Flow
500 automobile, chemical, and pharmaceutical companies that actually run businesses here. Those latter companies know the market and have done very well as a result. "If you're going to invest in emerging markets," he continues, "you also... View Details
Keywords: Dun Gifford, Jr.
- Web
Kraft Accelerator
School, Founder, Multiple Myeloma Research Foundation Kathy Giusti is a thinker, motivator, and, above all, a doer. Following her cancer diagnosis, the former pharmaceutical executive channeled her frustration over limited treatment... View Details
- 01 Dec 2003
- News
The Next Big Thing
life-sciences center of the world, by virtue of its unsurpassed “cluster” of world-renowned universities and teaching hospitals; medical-device, biotech, and pharmaceutical companies; financial firms; and skilled workers. “The leadership... View Details
- 23 Mar 2010
- First Look
First Look: March 23
catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
Keywords: Martha Lagace
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers... View Details
Keywords: by Bill George
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
talent pool in the US biomedical field that is second to none. And the only way to get that talent is for companies-both domestic and foreign-to do their R&D here. That's why pharmaceutical and biotechnology companies from around the... View Details
- 17 Jan 2008
- Working Paper Summaries
Competition in Modular Clusters
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)